Pharma/Biotech - Page 1 | TalkMarkets
All Posts > Content under Pharma/Biotech
1 to 16 of 1796 Posts
1 2 3 ... 113
6 Best Stocks For Value Investors This Week – March 26, 2017
Article By: Benjamin Clark
Sunday, March 26, 2017 6:11 PM EDT
I evaluated 25 different companies and only 6 were found to be undervalued or fairly valued and suitable for Defensive and/or Enterprising Investors. Therefore, these companies are the best undervalued stocks of the week.
In this article: CVG, CVS, AMGN, CVCO, SYKE, CWB
Market Pauses As Trump’s Agenda Faces First Setback
Article By: Yale Bock
Saturday, March 25, 2017 5:37 PM EDT
If you are in business, especially in the investment world, you are trying to find leaders who specialize in solving difficult issues in the toughest of conditions. Not every business cycle will be good, often there are plenty of economic headwinds.
In this article: F, PFE, VZ, AAPL, SBUX
AstraZeneca & Valeant Facing New Competition In The Opioid-Induced Constipation Arena
Article By: Lorimer Wilson
Friday, March 24, 2017 7:48 PM EDT
AstraZeneca & Valeant have been battling it out in the opioid-induced constipation arena with movantik and relistor, respectively, since winning their FDA approvals back in September 2014. Now there’s a third competitor prepping to jump into the mix.
In this article: AZN, VRX, SGIOF
E Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
Article By: Abba's Aces
Friday, March 24, 2017 5:52 PM EDT
Gilead is advancing a Crohn's treatment to Phase 2 but even if it passes Phase 3, it won't be the solution to GILD's problems..
In this article: GILD Also: GLPG
Could Technical Analysis Have Saved Bill Ackman?
Article By: Macro-Ops
Friday, March 24, 2017 1:33 PM EDT
It’s crucial to have a reliable and objective risk management process for when things go south. Without it, you’re setting yourself up to follow in Ackman’s shameful footsteps.
In this article: VRX
Novartis Spinning Out 2 Phase IIb-Ready Drugs To PureTech Health For An Equity Stake
Article By: Lorimer Wilson
Friday, March 24, 2017 1:10 PM EDT
Novartis is spinning out a pair of Phase IIb-ready drugs to Boston-based start-up PureTech Health, setting up a subsidiary called resTORbio which it will now fund, in tranches, with $15 million.
In this article: NVS
Merck KGaA And Pfizer Get FDA Approval Of Checkpoint Inhibitor "Avelumab" For Rare Merkel Cell Skin Cancer Therapy
Article By: Lorimer Wilson
Friday, March 24, 2017 10:17 AM EDT
Biopharma partners Merck KGaA and Pfizer came away with their first FDA approval of the checkpoint inhibitor avelumab, making it the fourth drug in this category to make it to the market.
In this article: MRK, PFE Also: AZN, BMY
The Market’s Patience Won’t Last Long
Article By: Geoff Bysshe
Thursday, March 23, 2017 10:30 PM EDT
Today the market was patient, but we shouldn’t expect that to be the case if Washington continues to delay or disappoint. When people are in a bad mood, they’re generally not very patient, and the same could be said for the market.
In this article: IBB, QQQ, DIA, IWM, IYT, KRE, SMH, SPY, XRT Also: GDX, GLD, SLV, TAN, TLT, USO, UUP
Sanofi To Buy Flexion Therapeutics, Inc. For +$1 Billion In Cash
Article By: Lorimer Wilson
Thursday, March 23, 2017 6:04 PM EDT
Sanofi is in talks to buy Flexion Therapeutics, Inc. a Boston-area biotech with its lead product now awaiting FDA approval, for more than $1 billion in cash, according to a source close to the deal.
In this article: SNY, FLXN Also: JNJ, PFE
Ultragenyx Pharmaceutical Inc. Drug "UX007" Fails Phase II Trial - Stock Tumbles
Article By: Lorimer Wilson
Thursday, March 23, 2017 1:23 PM EDT
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases reported that its drug UX007 failed a Phase II trial causing its stock to plummet.
In this article: RARE
Teva Pharmaceutical Industries Ltd. In Turmoil, Plans To Cut 11% Of Its Workforce After Passover
Article By: Lorimer Wilson
Thursday, March 23, 2017 10:17 AM EDT
With its executive suite in turmoil, its flagship drug under attack and its books burdened by debt following years of drought in its R&D arm, TEVA is reportedly preparing to unleash a major reorganization that will cost thousands of jobs.
In this article: TEVA Also: AGN
Why I'm Long Shares Of HedgePath Pharma
Article By: Jason Napodano
Wednesday, March 22, 2017 12:44 PM EDT
HedgePath remains an attractive story for small-cap biotech investors. The company is likely to report positive top-line Phase 2b results during the first half of 2017.
In this article: HPPI
E Therapix Biosciences: Small IPO With Big League Potential
Article By: Stone Fox Capital
Wednesday, March 22, 2017 11:48 AM EDT
Therapix Bio offers investors an under the radar IPO in the hot cannabinoid market with a promising pipeline.
In this article: THXBY, TRPX Also: GWPH, ZYNE, OWCP, CNBX
Novartis Flubs Primary Endpoint With Heart Drug Serelaxin
Article By: Lorimer Wilson
Wednesday, March 22, 2017 11:00 AM EDT
Novartis has reported that its 4-year study of the heart drug serelaxin has flubbed the primary endpoint, failing to significantly cut the rate of cardiovascular death or reduce worsening heart failure among patients with acute heart failure.
In this article: NVS Also: REGN, AMGN
Who Are The Next Acquisition Targets In Dermatology?
Article By: Ari Zoldan
Wednesday, March 22, 2017 8:25 AM EDT
Specialty pharmaceuticals is a highly dynamic sector with robust stock valuations and an active mergers & acquisition market. One of the most attractive areas for investment is dermatology.
EMA Gives Thumbs-Up To Actinium's Phase 3 SIERRA Program
Article By: Jason Napodano
Tuesday, March 21, 2017 10:07 AM EDT
Today's news is very positive for Actinium. Enrollment in SIERRA continues on plan and there are DMC updates expected around the middle of the year and again potentially at year end.
In this article: ATNM
1 to 16 of 1796 Posts
1 2 3 ... 113